Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter VEGF (Ranibizumab Biosimilar) Antikörper

Reaktivität: Human FACS, in vivo Wirt: Maus Monoclonal unconjugated Fab fragment Recombinant Antibody
Produktnummer ABIN7200657
  • Target Alle VEGF (Ranibizumab Biosimilar) Produkte
    VEGF (Ranibizumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Fragment
    Fab fragment
    Reaktivität
    Human
    Wirt
    • 1
    Maus
    Klonalität
    • 1
    Monoklonal
    Konjugat
    • 1
    Dieser VEGF (Ranibizumab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Verwendungszweck
    Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)
    Spezifität
    The Fab protein ranibizumab specifically binds to the human VEGF-A.
    Produktmerkmale
    Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.
    Aufreinigung
    Protein A affinity column
    Reinheit
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterilität
    0.2 μm filtered
    Endotoxin-Niveau
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.
  • Applikationshinweise
    Functional assay, neutralization.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Konservierungsmittel
    Without preservative
    Handhabung
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Haltbarkeit
    12 months
  • Target
    VEGF (Ranibizumab Biosimilar)
    Abstract
    VEGF (Ranibizumab Biosimilar) Produkte
    Synonyme
    MVCD1 antikoerper, VEGF antikoerper, VPF antikoerper, vascular endothelial growth factor A antikoerper, VEGFA antikoerper
    Substanzklasse
    Biosimilar
    Hintergrund
    The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.

    Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
Sie sind hier:
Kundenservice